Clinical Trials | November 24, 2025
Contineum MS drug stumbles in mid-stage trial
Topline results from the Phase 2 VISTA trial show that PIPE-307 did not meet its primary or secondary efficacy endpoints
Topline results from the Phase 2 VISTA trial show that PIPE-307 did not meet its primary or secondary efficacy endpoints
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
Cardiovascular disease (CVD) is the leading cause of death in the US and worldwide with over 82 million Americans living with CVD
The new MimixTM GeniTM reference standards were developed from the extensively tested Genome-in-a-Bottle Consortium (GIAB) cell line
The device delivers clear, high-quality images to support accurate diagnoses across a broad range of patient groups
Enzomenib, an oral, small-molecule inhibitor designed to disrupt the menin-MLL protein interaction involved in leukemogenesis
The antibody was designed and developed at Abzena’s Cambridge, UK,
New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain
FineCross M3 empowers physicians to perform safer PCI procedures, helping improve outcomes in patients with challenging coronary anatomies
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
